Trial · NCT04170556
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
NCT04170556, Phase 1, Phase 2, Completed, Fundacion Clinic per a la Recerca Biomédica
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING). Trials, record NCT04170556. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04170556
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)
- NCT number
- NCT04170556
- Status
- Completed
- Phases
- Phase 1, Phase 2
- Enrollment
- 69 participants, actual
- Lead sponsor
- Fundacion Clinic per a la Recerca Biomédica
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Regorafenib, Nivolumab
- First posted
- 2019-11-20
- Last updated
- 2024-09-03
- Other registries' IDs
- eudract:2019-003108-10
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment-Emergent Adverse Events | Up to 24 months | Rate of adverse events (AE) |
| Primary | Incidence of related Treatment-Emergent Adverse Events | Up to 24 months | Rate of related-AEs |
| Primary | Incidence of Treatment-Emergent Adverse Events | Up to 24 months | Rate of death |
| Secondary | Overall survival (OS) | Up to 24 months | Time from the date of start of treatment until the date of death |
| Secondary | Time to progression (TTP) | Up to 24 months | Time from the date of start of treatment until the date of objective disease progression or death |
| Secondary | Objective response rate (ORR) | Up to 24 months | Time from the date of start of treatment until the date of objective response |
| Secondary | Pattern of progression | Up to 24 months | Time from the date of start of treatment until the date of objective response |
| Secondary | Post-progression survival (PPS) | Up to 24 months | Time from the date of disease progression until the date of death |
| Secondary | Rate of patients who develop new extra-hepatic spread | Up to 24 months | Time from the date of start of treatment until the date of objective new extra-hepatic progression |
| Secondary | Serum and tissue marker characterization | Up to 24 months | Time from the date of start of treatment until the date of objective disease progression or death |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04170556
GET https://conductscience.org/api/trials/v1/NCT04170556/registered